GLP1R and diabetic kidney disease: In recent years, newer classes of medications emerged such as sodium-glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonist, endothelin antagonists, and mineralocorticoid receptor antagonists (MRAs) are all showing great promise in the battle against DKD and its cardiovascular morbidity.